TDO

test

Jun 15 2020   NTRC, Pelago Bioscience and Pangaea Oncology to collaborate in Eurostars project to develop a novel biomarker platform for immuno-oncology

May 18 2020   Novel screening assay for Arginase-1 inhibitors published in SLAS Discovery

Nov 29 2019   New structural insights into Arginase-1, a target for cancer immunotherapy

Nov 5 2019   Approach for Predictive Precision Medicine at ELRIG 2019 Drug Discovery Conference

Oct 21 2019   Predictive Precision Medicine Approaches at Molecular Targets and Cancer Therapeutics Conference

Mar 27 2019   NTRC and Radboud explore new methods to predict chemotherapy response in ovarian cancer

Mar 20 2019   Effective discovery of synergistic combinations by in silico prioritization

Feb 12 2019   Tissue-type analysis included in Oncolines™ cancer cell line profiling

Nov 21 2018   NTRC expands ResidenceTimer™ kinase panel with CDKs, MERTK, TYRO3 and GSKβ

Nov 12 2018   NTRC launches the first High-throughput Screening Assay for Arginase-1 inhibitors at ENA2018

Nov 1 2018   New predictive drug response biomarkers for approved kinase inhibitors

Oct 28 2018   NTRC presents at Rare Diseases and Orphan Drugs conference

Sep 26 2018   Oncolines™ at Discovery on Target conference in Boston

Jun 29 2018   NTRC presents at European Association of Cancer Research conference in Amsterdam

Jun 10 2018   NTRC expands OncolinesProfiler™ reference compound database to 162 anti-cancer agents

Apr 11 2018   NTRC presents novel high-throughput screening assay for Arginase I inhibitors for cancer immunotherapy at AACR Annual Meeting in Chicago

Apr 5 2018   NTRC expands ResidenceTimer™ platform with BTK resistance mutants

Mar 25 2018   NTRC expands SynergyFinder™ platform with triple combination testing

Feb 22 2018   NTRC includes Growth Rate metric evaluation in Oncolines™ profiling

Nov 15 2017   NTRC at Pivot Oncology conference Breakthroughs in Precision Cancer Treatment

Nov 10 2017   Target residence time-guided lead optimization at the European Pharma Summit in Berlin

Oct 16 2017   Pharmacogenomic analysis at Molecular Targets and Cancer Therapeutics conference

Oct 11 2017   Novel synergistic combinations identified by unbiased high-throughput screening

Sep 25 2017   NTRC’s key TTK kinase inhibitor patent granted in US

Sep 19 2017   Meet NTRC at Discovery on Target conference in Boston 25 – 29 September, 2017

Jul 28 2017   NTRC publishes an association of CTNNB1 mutant status and increased cancer cell line sensitivity to TTK inhibitors

Jun 23 2017   NTRC expands Oncolines™ cell line panel to 102 cell lines

May 22 2017   NTRC publishes target residence time-guided optimization of TTK inhibitors

Mar 30 2017   NTRC launches GeneNominator™ tool for drug sensitivity and gene expression analysis

Mar 27 2017   Meet NTRC at booth #3050 AACR 2017 in Washington D.C.

Mar 16 2017   New study in Oncotarget shows that stable aneuploid cells are more sensitive to TTK inhibition than chromosomally unstable cell lines

Jan 2 2017   Kinetic parameters of 80 kinase inhibitors available online through the Journal of Molecular Biology

Dec 23 2016   Structural insight into the function of TDO in healthy aging

Dec 23 2016   New drug combinations addressing treatment resistance in childhood leukemia proposed based on SynergyFinder™

Dec 5 2016   NTRC’s Oncolines™ profiling is cover story in December issue of Molecular Cancer Therapeutics

Nov 10 2016   NTRC presents on ResidenceTimer™ and OncolinesProfiler™ at 28th EORTC-NCI-AACR symposium in Munich

Sep 18 2016   NTRC to join EU mission to Japan and to present at BIO Japan

Sep 2 2016   Comparative Oncolines™ profiling of 122 anti-cancer agents published in Molecular Cancer Therapeutics

Aug 25 2016   NTRC presents on ResidenceTimer™ at Discovery on Target conference in Boston

Jul 6 2016   NTRC presents OncolinesProfiler™ and TTK program at EACR in Manchester

Apr 28 2016   Novel synergistic drug combinations proposed for pediatric T-cell leukemia

Apr 8 2016   NTRC expands number of cancer genes analyzed in Oncolines™ cell line panel

Apr 8 2016   NTRC presents on TTK kinase program at AACR conference

Jan 15 2016   NTRC team of cyclists will conquer the Alpe d’Huez to raise funds for cancer research

Dec 9 2015   NTRC has identified IDO1 inhibitors with best-in-class properties by screening at the European Lead Factory

Dec 4 2015   NTRC and Vipergen receive Eurostars support for cancer immunotherapy research

Sep 14 2015   NTRC launches comparative cancer cell line profiling

Aug 31 2015   NTRC presents at Discovery on Target conference in Boston

Jul 10 2015   Novel therapeutic target proposed to increase the efficacy of taxane chemotherapy

Jul 8 2015   Whole genome doubling causes multidrug resistance

Jun 14 2015   NFK GreenScreen™ and TTK program presented at EACR-AACR conference in Florence

May 27 2015   Selective targeting of cancer driver genes by combinations of existing drugs published in PLOS ONE

Apr 28 2015   TTK drug discovery program presented at Protein Kinases conference in Berlin

Apr 7 2015   SynergyFinder™ presented at AACR 2015 in Philadelphia

Apr 7 2015   ResidenceTimer™ and TTK drug discovery program presented at Drug Discovery Chemistry meeting in San Diego

Apr 3 2015   NTRC receives Michael J. Fox Foundation support for TDO program for Parkinson’s disease

Feb 22 2015   TTK program and SynergyFinder™ presented at TAT 2015 conference in Paris

Feb 18 2015   NTRC receives qualified hit series for TDO from the European Lead Factory

Jan 15 2015   NTRC launches assay for mouse IDO1 and mouse TDO activity

Jan 7 2015   NTRC and Utrecht University start collaborative research project on Parkinson’s disease

Nov 12 2014   SynergyFinder™ and NFK GreenScreen™ presented at EORTC-NCI-AACR conference in Barcelona

Nov 12 2014   NFK GreenScreen™ presented at CHAINS conference in Veldhoven

Oct 1 2014   NTRC launches Oncolines™ 66 cell line panel

Sep 5 2014   ResidenceTimer™ will be presented at the EFMC-ISMC symposium 2014

Aug 25 2014   Reverse Phase Protein Array workshop in Paris sponsored by NTRC

Aug 25 2014   NTRC will present at 8th International Protein Kinase Inhibitors conference in Warsaw

Jun 27 2014   Oncolines™ and SynergyFinder™ presented at EACR 2014 in Munich

Jun 2 2014   NTRC publishes high-throughput screening assay for IDO1 and TDO in Journal of Biomolecular Screening

May 14 2014   NTRC will present at Discovery Partnerships Conference in Berlin

May 5 2014   NTRC will attend BIO 2014 in San Diego

May 5 2014   NTRC will present at Protein Kinases in Drug Discovery Conference in Berlin

Apr 13 2014   NTRC launches new service ResidenceTimer™ at Drug Discovery Chemistry conference in San Diego

Mar 27 2014   Oncolines™ and kinome profiling presented at AACR 2014 in San Diego

Mar 21 2014   NTRC publishes Oncolines™ profiles of all marketed small molecule kinase inhibitor drugs in PLOS ONE

Mar 7 2014   NTRC will present at Drug Discovery Innovations Conference 2014

Feb 15 2014   NTRC will present at Frontiers in Medicinal Chemistry 2014 in Tübingen.

Feb 6 2014   NTRC will present at BioEurope Spring 2014

Feb 6 2014   NTRC reaches new milestones in their drug discovery programs and expands business development activities

Dec 10 2013   NTRC extends the roll-out of its services Oncolines™ and SynergyFinder™ and the kinase profiling services of Carna Biosciences Inc.

Nov 12 2013   NTRC provides high-throughput screening services together with Pivot Park Screening Centre

Oct 14 2013   NTRC to partner with European centers of excellence in training network for next generation cancer researchers

Oct 13 2013   NTRC will present at BioEurope 2013

Sep 26 2013   Oncolines™ presented at the European Cancer Congress 2013

Nov 19 2012   NTRC and Carna join forces in the marketing of drug discovery services in Europe and Japan

Nov 13 2012   NTRC obtains exclusive license for Merck kinase candidate compounds

Jun 6 2012   NTRC starts at the Life Sciences Park Oss